NXC-201 is the only CAR-T therapy currently being studied for AL amyloidosis, and the FDA's RMAT designation highlights the potential of this novel therapy to address unmet medical needs in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback